CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report

JCO Precis Oncol. 2024 Apr:8:e2300677. doi: 10.1200/PO.23.00677.

Abstract

NSCLC w/EGFRex19del & MET amp: durable intracranial + systemic response to amivantamab/osimertinib.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides*
  • Aniline Compounds*
  • Antibodies, Bispecific*
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • ErbB Receptors / genetics
  • Humans
  • Indoles*
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines*

Substances

  • osimertinib
  • amivantamab
  • Protein Kinase Inhibitors
  • ErbB Receptors
  • Acrylamides
  • Antibodies, Bispecific
  • Aniline Compounds
  • Indoles
  • Pyrimidines